Myriad Genetics (MYGN) Expected to Post Earnings on Thursday

Myriad Genetics (NASDAQ:MYGN) is expected to be releasing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Myriad Genetics to announce earnings of ($0.03) per share and revenue of $206.0260 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Myriad Genetics had a negative return on equity of 8.51% and a negative net margin of 48.24%.The business had revenue of $200.40 million for the quarter, compared to analyst estimates of $202.42 million. During the same period in the prior year, the company earned ($0.03) EPS. The company’s revenue was up 2.3% on a year-over-year basis. On average, analysts expect Myriad Genetics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Myriad Genetics Price Performance

Myriad Genetics stock opened at $5.32 on Wednesday. Myriad Genetics has a one year low of $3.53 and a one year high of $8.59. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.19 and a current ratio of 2.40. The business has a fifty day moving average of $5.06 and a two-hundred day moving average of $4.97. The company has a market cap of $502.46 million, a P/E ratio of -1.24 and a beta of 1.64.

Wall Street Analyst Weigh In

MYGN has been the subject of several recent analyst reports. Wells Fargo & Company reduced their price objective on shares of Myriad Genetics from $6.00 to $5.50 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. TD Cowen lowered their target price on shares of Myriad Genetics from $7.00 to $6.00 and set a “hold” rating on the stock in a research report on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of Myriad Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $6.50.

Insider Activity

In related news, Director Rashmi Kumar sold 15,000 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $4.46, for a total value of $66,900.00. Following the sale, the director directly owned 171,889 shares of the company’s stock, valued at approximately $766,624.94. This represents a 8.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Paul Bisaro bought 7,500 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were acquired at an average price of $3.69 per share, with a total value of $27,675.00. Following the completion of the acquisition, the director directly owned 97,441 shares in the company, valued at $359,557.29. This represents a 8.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Alliancebernstein L.P. raised its position in shares of Myriad Genetics by 1.8% during the 3rd quarter. Alliancebernstein L.P. now owns 101,234 shares of the company’s stock worth $732,000 after purchasing an additional 1,784 shares during the last quarter. Legal & General Group Plc increased its position in Myriad Genetics by 1.0% during the second quarter. Legal & General Group Plc now owns 237,688 shares of the company’s stock worth $1,262,000 after buying an additional 2,313 shares in the last quarter. Quarry LP raised its holdings in shares of Myriad Genetics by 155.6% in the fourth quarter. Quarry LP now owns 4,365 shares of the company’s stock worth $27,000 after acquiring an additional 2,657 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Myriad Genetics by 2.7% in the fourth quarter. Franklin Resources Inc. now owns 103,374 shares of the company’s stock worth $636,000 after acquiring an additional 2,714 shares during the last quarter. Finally, Royal Bank of Canada lifted its position in shares of Myriad Genetics by 129.6% in the fourth quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock valued at $31,000 after acquiring an additional 2,818 shares in the last quarter. 99.02% of the stock is owned by hedge funds and other institutional investors.

Myriad Genetics Company Profile

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.